Verified Panel · Mobile-First CAWI · IRB-Ready
Designed around the population, not the platform
Survey research in rare diseases is not a scaled-down version of general patient research. In fact, the populations are smaller, the recruitment windows are longer, and the cognitive and physical burdens on respondents are often higher. Moreover, the statistical assumptions that govern standard power calculations frequently do not hold.
Consequently, MedPanel’s rare disease patient survey research practice is built around these realities — combining a verified, globally recruited panel with survey design expertise specific to low-prevalence conditions. As a result, the data is both statistically defensible and genuinely representative of the population you are trying to understand.
Survey Methodology for Rare Conditions: Getting the Instrument Right
MedPanel deploys Computer-Assisted Web Interviewing (CAWI) as the primary methodology for rare disease patient surveys — a format that supports structured questionnaire logic, skip patterns, and multimedia stimulus delivery without requiring participants to coordinate schedules around a moderated session. Furthermore, CAWI is particularly well-suited to rare disease populations because it accommodates geographic dispersion, variable daily energy levels, and the reality that many patients manage complex care routines alongside research participation.
Importantly, all surveys are built mobile-first. A significant proportion of rare disease patients — particularly those with mobility limitations, hospitalization histories, or pediatric and caregiver respondents managing on behalf of a patient — complete surveys on smartphones or tablets. Therefore, a questionnaire that renders correctly only on desktop is a questionnaire that loses respondents at the point of access, introducing systematic bias into your sample.
Structured questionnaires in rare disease settings also require additional attention to branching logic. For example, rare conditions frequently present with heterogeneous symptom profiles, variable disease progression, and treatment histories that span approved therapies, compassionate use, and clinical trial participation. A well-constructed rare disease survey instrument accounts for this heterogeneity through precise eligibility screening embedded in the survey flow — not applied retrospectively during data cleaning.
Patient Surveys vs Physician Surveys — Design and Length Are Not Interchangeable
Rare disease research frequently requires parallel data collection from both patients and the physicians who treat them. However, these are not the same survey with the audience label changed. They require fundamentally different design logic.
- Patient surveys in rare disease settings should target a maximum of 15–20 minutes of active completion time under most circumstances. Otherwise, longer instruments risk non-completion from fatigue, particularly for patients with neurological conditions, chronic pain, or conditions that impair concentration. In addition, question formats matter: validated scales (EQ-5D, PGIS, specific disease-burden instruments) should be used where they exist, but they must be evaluated for relevance to the specific condition rather than imported wholesale from general chronic disease research.
- Physician surveys can tolerate greater length — typically 20–30 minutes — and carry different design priorities. Notably, in rare disease many treating physicians see only a small number of affected patients per year. Therefore, survey design must account for this by anchoring questions to specific patient cases or realistic clinical scenarios rather than aggregate experience. Questions that ask a rare disease specialist to estimate population-level trends they have never observed firsthand produce unreliable data.
Accordingly, MedPanel’s survey design team works with medical writers experienced in rare disease clinical practice to ensure physician instruments reflect the actual treatment decision environment.
Sample Size, Power, and Realistic Expectations
One of the most consequential conversations in rare disease patient survey research is the one about sample size — and it needs to happen before instrument design begins, not after recruitment closes.
Standard power calculations assume sample sizes that rare disease populations cannot support. For instance, a condition with 10,000 diagnosed patients in a target market, variable levels of patient organization engagement, and a realistic recruitment conversion rate may yield a completed survey sample of 50–120 respondents. However, that ceiling is not a methodological failure — it is a population reality that must be built into your analysis plan from the outset.
Consequently, MedPanel conducts feasibility assessments prior to every rare disease survey program to establish an honest recruitment ceiling based on verified panel depth, condition prevalence data, and historical conversion rates for comparable studies. This upstream step protects sponsors from committing to statistical assumptions that the population cannot support. In addition, it gives regulatory and HEOR teams the documentation they need to justify sample size decisions in submissions and publications.
For ultra-rare conditions, MedPanel recommends treating quantitative survey data as complementary to, rather than a replacement for, qualitative research — a combined-methods approach that extracts maximum insight from small but verified samples. Indeed, this methodology is well-supported in the rare disease HEOR research literature and increasingly expected by HTA bodies evaluating evidence packages for orphan therapies.
Fatigue, Accessibility, and Cognitive Burden in Rare Disease Survey Design
Participant burden is an ethical and a data quality issue simultaneously. Specifically, a survey that is too long, too cognitively demanding, or inaccessible to respondents with the relevant condition will produce incomplete responses, satisficing behavior, and dropout patterns that bias your results in ways that are difficult to detect in analysis.
Accordingly, MedPanel applies condition-specific burden guidelines at the instrument design stage.
- Significant neurological involvement — for example, lysosomal storage disorders, certain muscular dystrophies, and rare epilepsies. In these cases, question complexity and reading level targets are set conservatively. Response scales are simplified where validated instruments permit.
- Pediatric rare diseases where caregiver proxy response is the primary data source. Here, instruments are reviewed for the cognitive burden placed on caregivers who are themselves managing high-stress clinical and logistical environments.
- Progressive conditions where patient health status may change over the fielding window. In addition, survey instruments include date-stamped status anchors to ensure responses can be correctly attributed to a specific point in the patient’s disease trajectory.
Furthermore, accessibility features — screen reader compatibility, adjustable font rendering, keyboard navigation support — are standard across all MedPanel CAWI deployments, not optional add-ons. For conditions affecting vision, fine motor control, or speech, MedPanel can deploy assisted-completion protocols in coordination with site-based patient support staff.
Panel Verification and Global Reach in Rare Disease Recruitment
Recruitment integrity is the single most important variable in rare disease patient survey research.
Importantly, self-reported panels — where individuals self-identify as having a rare condition without independent verification — carry significant misrepresentation risk. This is particularly true for conditions that share symptom profiles with more common diagnoses, or where there is a strong patient community with high research participation incentives.
By contrast, MedPanel’s panel is verified. Diagnosis confirmation draws on a combination of physician attestation, medical record review, and condition-specific screener instruments designed with clinical input. Admittedly, this process adds time to recruitment setup. However, it is worth every day, because it means the data you collect reflects the population you specified, not an approximation of it.
Meanwhile, our global panel spans North America, Europe, and growing coverage across Asia-Pacific and Latin America. As a result, we can support international rare disease surveys for global regulatory submissions, cross-market HEOR analyses, and multinational rare disease research programs that connect to your broader rare disease research pillar strategy.
Design your survey
Design Your Rare Disease
Survey with MedPanel
Every rare disease survey program starts with a feasibility conversation. Specifically, MedPanel’s research team will review your target population, confirm panel depth, assess realistic sample expectations, and outline an instrument design and fielding timeline calibrated to your study objectives.
Target population review
Panel depth confirmation
Realistic sample expectations
Instrument design & fielding timeline
Contact MedPanel to begin scoping your rare disease patient survey research program. Bring your protocol draft or your research questions — we will meet you where you are.